New ADHD Treatment Will Go on Hip

BETHESDA, MD, 06 April 2006 — The Food and Drug Administration (FDA) announced today that it had approved the marketing of Daytrana, a methylphenidate transdermal system designed to be worn nine hours a day on the hip by children ages 6 to 12 who have attention-deficit/hyperactivity disorder (ADHD).
Thomas Laughren, director of the FDA Division of Psychiatry Products, said the patch "provides an alternative route of administration for methylphenidate."
A substantial percentage of children have difficulty swallowing tablets and capsules, Laughren said he and other FDA officials were told in December when the agency asked an advisory committee to discuss the merits and disadvantages of making a methylphenidate patch available for youngsters with ADHD.

For information, resources and practical strategies on autism visit:

www.child-autism-parent.cafe.com

www.AutismConcepts.com